CAMP4 THERAPEUTICS CORPORATION
CAMP
Positions held
Your positionsCAMP isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $232.19M | Enterprise value | $148.16M | Trailing P/E | — | Forward P/E | -4.58 |
| PEG | — | Price / book | -284.62 | Beta | — | Dividend yield | 0.00% |
| Revenue growth | 18.8% | Earnings growth | — | Gross margin | 0.0% | Operating margin | -7.5% |
| Profit margin | 0.0% | ROE | -5.5% | ROA | -45.3% | Debt / equity | — |
| Current ratio | 4.70 | Free cash flow | -$12.83M | Analyst recommendation | strong_buy | Mean target | $10.57 |
| 52w high | $7.75 | 52w low | $2.86 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $1.8M | $1.3M | $0.3M | $0.8M | $1.5M | — |
| Op margin | -752.1% | -1010.1% | -3671.3% | -1655.0% | -870.3% | — |
| Net income | -$33.5M | -$18.3M | -$40.3M | -$15.1M | -$12.6M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$13.4M | -$13.1M | -$12.8M | -$13.2M | -$13.0M | — |
- Revenue +37% vs prior quarter ($1.8M vs $1.3M).
- Operating margin expanded to -752.1%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $3.5M | $0.7M | $0.3M | $0.0M |
| Op margin | -1488.3% | -8142.3% | -14822.6% | — |
| Net income | -$80.4M | -$51.8M | -$49.3M | -$44.2M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$52.1M | -$53.1M | -$51.9M | -$45.0M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-05 · Oppenheimer Initiates Coverage on CAMP4 Therapeutics With Outperform Rating, $15 Price Target
2026-09-29 · Chardan Trims Price Target on CAMP4 Therapeutics to $6 From $6.50, Keeps Buy Rating
2026-09-28 · CAMP4 Targets Q4 ASCEND Trial Start for SYNGAP1 Therapy CMP-002
2026-09-10 · CAMP4 Therapeutics Gets Clearance to Conduct Phase 1/2 Study for SYNGAP1-Related Disorder Treatment in UK
2026-09-01 · CAMP4 to Participate in Upcoming Investor Conferences
2026-08-21 · Camp4 Therapeutics Insider Sold Shares Worth $879,719, According to a Recent SEC Filing
2026-08-13 · CAMP4 Therapeutics Corporation (CAMP) Reports Q2 Loss, Tops Revenue Estimates
2026-08-13 · CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights
2026-08-04 · CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement
2026-08-03 · CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Tops Revenue Estimates
Price (daily)
Full chart · RSI · MACD · patterns